実臨床においてbevacizumabが大腸癌の腫瘍微小環境に与える影響

• Project/Area Number: 19K16784
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50010:Tumor biology-related
• Research Institution: Kindai University
• Principal Investigator: 武川 直樹 近畿大学, 医学部, 助教 (30734686)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Project Status: Declined (Fiscal Year 2019)
• Budget Amount: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000); Fiscal Year 2021: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000); Fiscal Year 2020: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000); Fiscal Year 2019: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)